On 18 February 2020, OEL (Holdings) Limited restructured its wholly-owned subsidiary, AJJ HEALTH CARE MANAGEMENT PTE. LTD (AJJ). On 1 April 2020, shareholders'approval was granted for the Group to diversify its core business into the high tech healthcare sector, following which AJJ successfully acquited a 51%-stake in a China-based healthcare company Shanghai Longjian Hospital Management Co. Ltd. Registered on 7 March 2019 in Shanghai, China, Shanghai Longjian is a healthcare organization engaged in the operation, medical investment consulting and health service management. The company's legal representative, Dr. Ye Wenzheng, is one of the most authoritative representatives of hematology in China and has made three "first discoveries" in the field of medical research in China. In addition, the company has a number of top medical experts, including Tang Guomin, Wang Zhifang and Jiang Wei. Dr. Ye Wenzheng will continue to lead the acquired Shanghai Longjian in the areas of expanding specialty hospital care and geriatric care management, medical devices and pharmaceuticals consumer industry businesses.
Leveraging on Shanghai Longjian's medical expertise and its network in China, OEL is committed to bringing in the HIFU technology - a well-researched and proven technology that is able to treat tumours and certain cancers. HIFU, or High Intensity Focused Ultrasound, is the latest non-invasive technology for tumour and cancer treatment by using focused ultrasound. It is recognized globally in the US and other major European countries where incidences of cancer are high.
HIFU treatment for prostate cancer gained traction due to the high success rate but it has been used to treat bone, brain, breast, liver, pancreas, kidney and rectum cancers.
By using beams of ultrasound to destroy cancerous cells without damaging surrounding normal tissue (similar to using a magnifying glass to focus sunlight), this technology enables tumours to be treated without surgery hence it can be done as a day procedure with minimal effect to the patients and little downtime after the treatment. It improves patients’ quality of life and decreases the cost of care for cancer patients.
Our joint-venture partners manufacture the HIFU-2001 and HIFUNIT 9000, which are now the leading global HIFU technology with its multi-dimensional imaging capability that allows for surgical precision. These HIFU technologies that can treat tumours and cancers are backed by proven track and safety records.
